Invokana Lawsuits Move Forward, With Issuance of Two New Orders in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports

NEW YORK, May 15, 2017 /PRNewswire/ -- The federal multidistrict litigation overseeing hundreds of products liability lawsuits involving Invokana and Invokamet are moving forward in the U.S. District Court, District of New Jersey. According to an Order dated May 1, 2017, the Court has established an Initial Discovery Plan addressing, among other things, bellwether case selection protocol, scheduling and trial dates. The Court had previously indicated that the litigation's first bellwether trials could begin in September 2018. (IN RE: Invokana (Canagliflozin) Products Liability Litigation, MDL #2750)

According to an Order dated May 5, 2017, the Court has barred the filing of multi-plaintiff complaints, apart from those that name a derivative plaintiff, such as a spouse. Multi-plaintiff cases already pending in the litigation as of May 5^th are to be severed.

"Our Firm is representing many Invokana lawsuit plaintiffs, and we are monitoring this litigation closely. We are pleased that the Court is moving forward with plans for bellwether trials, as verdicts in these cases could provide some insight into how other juries might decide similar lawsuits involving Invokana or Invokamet," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to evaluate legal claims on behalf of Type 2 diabetes patients who were allegedly injured as result of Invokana or Invokamet.

Invokana and Invokamet Side Effects

Invokana was brought to market in March 2013, and was the first SGLT2 inhibitor approved by the U.S. Food & Drug Administration (FDA) to treat Type 2 diabetes. The agency approved Invokamet in November 2014. Both drugs lower blood glucose levels by preventing the absorption of sugar by the kidneys, thereby causing it to be eliminated via urine. 

The FDA has since issued several safety alerts to warn of side effects potentially associated with the use of Invokana and other SGLT2 inhibitors. In December 2015, for example, the agency announced that the labels for all drugs in this class would be updated to include information about diabetic ketoacidosis, a potentially deadly complication related to the accumulation of toxic acids (ketones) in the bloodstream. The labels were also modified with information about life-threatening blood infections (urosepsis) and kidney infections (pyelonephritis) that originate as urinary tract infections.

In June 2015, the FDA mandated  stronger kidney warnings for several SGLT2 inhibitors, including Invokana and Invokamet, after the medications were cited in more than 100 reports of acute kidney injury.

Court records indicate that just over 280 cases have been filed in the District of New Jersey on behalf of individuals who suffered ketoacidosis or kidney damage allegedly related to the use of Invokana or Invokamet.  Plaintiffs accuse the drugs' manufacturers of failing to warn patients about the serious risks potentially associated with the medications.

Bernstein Liebhard LLP continues provide free legal reviews to individuals who allegedly developed ketoacidosis or kidney damage due to treatment with Invokamet and Invokana. To learn more, please visit Bernstein Liebhard LLP's website, or call the Firm directly at 800-511-5092.

About Bernstein Liebhard LLP  
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 
800-511-5092

ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information: 
Sandy A. Liebhard, Esq. 
Bernstein Liebhard LLP 
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/  
https://plus.google.com/115936073311125306742?rel=author

SOURCE Bernstein Liebhard LLP

Related Links

http://www.bernlieb.com